Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series

Clin Lung Cancer. 2023 Nov;24(7):666-671. doi: 10.1016/j.cllc.2023.08.006. Epub 2023 Aug 6.
No abstract available

Keywords: Precision medicine; Targeted therapy; Toxicity management; Treatment response.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Chylous Ascites*
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Protein Kinase Inhibitors / adverse effects
  • Proto-Oncogene Proteins c-ret / genetics
  • Pyrazoles

Substances

  • selpercatinib
  • pralsetinib
  • Pyrazoles
  • Protein Kinase Inhibitors
  • RET protein, human
  • Proto-Oncogene Proteins c-ret